by Jakub Jarolím, Business Intelligence Department
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Sotio Biotech
1/5/2022
April 2022 Biotechnology: Review of news from the most innovative therapeutic areas and the business development transactions
Market
Continued lack of financing and M&A drought led to NBI 10% during April
Through all market cap tiers struggled over first quarter 2022, large cap biopharmas performed the strongest, which could be a positive signal for the sector as large caps tend to recover first. The continued lack of financing activity and M&A drought led to NBI losing 10% during April.
Antibody-Drug Conjugates
European Commision approved Padcev for locally advanced urothelial carcinoma
News detail
Share on social networks